AR
HRTX icon

Apeiron RIA’s Heron Therapeutics HRTX Stock Holding History

Apeiron RIA’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$158K Buy
370,579
+64,911
+21% +$52K 0.04% 162
2026
Q1 		$245K Buy
305,668
+45,700
+18% +$53K 0.06% 182
2025
Q4 		$359K Buy
259,968
+37,090
+17% +$45.8K 0.07% 153
2025
Q3 		$290K Sell
222,878
-37,500
-14% -$59.5K 0.07% 171
2025
Q2 		$539K Sell
260,378
-2,164
-0.8% -$4.42K 0.14% 118
2025
Q1 		$578K Hold
262,542
– – 0.17% 110
2024
Q4 		$402K Buy
262,542
+19,000
+8% +$30.8K 0.11% 138
2024
Q3 		$485K Buy
243,542
+54,907
+29% +$131K 0.14% 119
2024
Q2 		$660K Buy
188,635
+64,635
+52% +$199K 0.2% 88
2024
Q1 		$343K Buy
124,000
+41,000
+49% +$103K 0.1% 153
2023
Q4 		$141K Hold
83,000
– – 0.04% 198
2023
Q3 		$85.5K Buy
83,000
+31,000
+60% +$44.1K 0.03% 189
2023
Q2 		$60.3K Buy
52,000
+19,000
+58% +$33.9K 0.02% 191
2023
Q1 		$49.8K Buy
+33,000
New +$82.6K 0.02% 193

Other funds holding HRTX

CPC
Congress Park Capital Saratoga Springs, New York $370M AUM 26.01% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
DIM
DLK Investment Management Solana Beach, California $235M AUM 12.41% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
TWM
TopTier Wealth Management Muskego, Wisconsin $166M AUM
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
VWM
Venturi Wealth Management Austin, Texas $2.58B AUM 41.25% 1-Year Est. Return

Apeiron RIA's HRTX Position: Q2 2026 in Review

Apeiron RIA increased its Heron Therapeutics (HRTX) stake by 21% in Q2 2026, buying an estimated $52K and bringing the position to 370,579 shares worth $158K. The position accounts for 0.04% of the portfolio, ranked #162.

Apeiron RIA first reported a position in HRTX in Q1 2023 and has held it in 14 quarters since. The position peaked at $660K in Q2 2024. 14 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Apeiron RIA held 370,579 shares of Heron Therapeutics worth $158K as of Q2 2026.
  • Apeiron RIA bought 64,911 Heron Therapeutics shares in Q2 2026, an estimated $52K.
  • Heron Therapeutics made up 0.04% of Apeiron RIA's portfolio in Q2 2026, its #162 holding.
  • Apeiron RIA first reported a position in Heron Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Apeiron RIA's Heron Therapeutics position peaked at $660K in Q2 2024.
  • 14 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Apeiron RIA's 13F filing for Q2 2026, filed 16 Jul 2026.